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Introduction: Interleukin (IL)-33 is a proinflammatory cytokine contributing to the pathogenesis of rheumatoid
arthritis (RA). The gene encoding IL-33 may serve as a genetic factor and be associated with the risk of RA. To
investigate the potential association between IL33 and RA, we performed a case–control study based on Chinese
Han population.
Methods: A three-stage case–control study was performed. Two tag single-nucleotide polymorphisms (SNPs)
(rs7044343 and rs10975514), mapping to the IL33 gene, were first genotyped in the discovery population. We
further genotyped rs7044343 and rs10975514 in the validation and replication population. The associations
between the two tag SNPs and phenotypic subgroups of RA and levels of serum IL-33 were assessed with a
logistic regression model.
Results: In the discovery population, the CC genotype of rs7044343 was associated with RA patients (odds ratio
(OR) = 0.777, 95% confidence interval (CI), 0.611 to 0.988; P = 0.040). After anti-citrullinated peptide antibody (ACPA)
stratification, the CC genotype of rs7044343 was also shown to be a protective genotype in RA without ACPA
(OR = 0.610; 95% CI, 0.379 to 0.982; P = 0.042). In the validation population and replication population, the association
between rs7044343 and RA, especially ACPA-negative RA, was still significant. A meta-analysis of discovery, validation,
and replication panels confirmed the association between CC genotype of rs7044343 and RA (Pcombined = 0.0004;
ORcombined = 0.77; 95% CI, 0.67 to 0.89). No evidence was found for heterogeneity between three sample sets (Phet = 0.99;
I2 = 0%). Similar results were also obtained in ACPA-negative RA (Pcombined = 0.0002; ORcombined = 0.57; 95% CI, 0.43 to
0.77). No association was detected between rs10975514 polymorphism and RA susceptibility in the discovery and
validation population. The serum levels of IL-33 were significantly lower in the patients with the rs7044343 CC genotype.
Conclusion: The CC genotype of rs7044343 in IL33 is associated with RA patients and downregulates IL-33
expression in RA.Introduction
Rheumatoid arthritis (RA) is an autoimmune disease
characterized by chronic inflammation of synovial joints
without precisely known pathogenesis. Genetic factors
contribute to the development of RA; it was estimated
that the total heritability of RA is approximately 66% [1].
Current genome-wide association studies (GWASs) have
identified 46 genetic loci, such as HLA, PTPN22, and
CTLA4 associated with RA [2]; however, the identified
risk loci of RA have modest effect sizes (odds ratios in* Correspondence: murongster@gmail.com; li99@bjmu.edu.cn
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unless otherwise stated.the range of 0.78 to 2.78) and can explain only about
16% of the RA heritability [3]. Therefore, more popula-
tion-based studies are needed to find the genetic basis of
RA.
Interleukin (IL)-33 was recently identified as a member
of the IL-1 family and a ligand for the IL-1 family receptor
ST2 [4]. In patients with RA, immunohistochemistry and
in situ hybridization have identified IL-33 residing in the
synovial cells of inflamed joints [5]. The level of IL-33 was
elevated in both serum and synovial fluid and associated
with autoantibody production, bone erosion, and intersti-
tial lung disease [6,7]. In a murine model, IL-33 could ex-
acerbate collagen-induced arthritis (CIA) and elevate the
production of proinflammatory cytokines and anticollagenhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Information of IL33 SNPs from HapMap CHB database. All IL33 SNPs are in one block and in high linkage disequilibrium (LD) (D’ > 0.92).
The numbers present the r2 between the SNPs. Two SNPs (rs7044343 and rs10975514) were selected in this study. SNP, single-nucleotide polymorphism;
CHB, Han Chinese in Beijing.
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naling could attenuate the severity of CIA [9]. These stu-
dies suggest that IL-33 plays an important role in the
pathogenesis of RA and indicate that the IL33 genetic
variants associated with RA merit further investigation.
Methods
Patients and controls
In total, 1,952 patients with established RA and 1,755 unre-
lated healthy controls of Northern Han Chinese origin
were included in this study. The discovery population of
700 cases and 598 controls was assembled from Northern
Han Chinese; the validation population of 586 cases and
456 controls was assembled from southern China; and the
replication population of 666 cases and 701 controls was
assembled from both northern and southern China. All pa-
tients fulfilled the revised criteria of the American College
of Rheumatology for RA [10]. The healthy control subjects
were defined as healthy individuals without inflammatoryTable 1 Clinical characteristics of the study cohorts
Discovery population
Number of cases 700
Ethnicity Northern Han Chinese
Female, % 79.9
Age, mean ± SD years 54.0 ± 13.1
Age at RA onset, mean ± SD years 46.4 ± 16.0
Disease duration, mean ± SD years 8.1 ± 8.1
ACPA status, % positive 72.6
RF status, % positive 81.6
ACPA, anti-citrullinated proteins antibodies; RF, rheumatoid factor.arthritis by medical history, general examinations, and la-
boratory examinations and were individually matched to
RA cases on the basis of sex, ethnicity, and local residential
region. The study was approved by the ethics committee of
Peking University People’s Hospital (FWA00001384), and
informed consents were obtained from all participants.
After oral and written informed consents had been ob-
tained, genomic DNA and serum samples were extracted
from peripheral blood of patients and healthy controls.
The following clinical data were recorded for ascertain-
ment of the clinical phenotype of RA patients: age at RA
onset, sex, disease duration, and rheumatoid factor (RF)
and ACPA status.
Genotyping methods
Haplotypes from the HapMap database (Han Chinese in
Beijing, CHB) [11] were used to select tag SNPs (r2 = 0.8)
residing in IL33 (dbSNP data (build129)). In total, 16 SNPs
were identified in CHB. All SNPs were in one block andValidation population Replication population
586 666
Southern Han Chinese Northern and Southern
81.2 82.8
52.4 ± 13.9 54.3 ± 12.8
46.3 ± 15.0 46.6 ± 15.4
7.8 ± 7.3 9.0 ± 10.3
75.3 68.9
78.3 84.0
Table 2 Association analysis of rs7044343 with RA in the discovery population
Characteristic (n) Allele frequency (%) Genotype frequency (%) T versus C CC versus TT + TC CC + TC versus TT
T C TT TC CC OR (95% CI) OR (95% CI) OR (95% CI)
P value P value P value
Control (598) 545 (45.6) 651 (54.4) 137 (22.9) 271 (45.3) 190 (31.8)
RA (700) 641 (45.8) 759 (54.2) 127 (18.1) 387 (55.3) 186 (26.6) 1.009 0.777 1.354
(0.864-1.178) (0.611-0.988) (1.033-1.774)
0.912 0.040* 0.028*
RF + (418) 377 (45.1) 459 (54.9) 78 (18.7) 221 (52.9) 119 (28.5) 0.981 0.855 1.308
(0.822-1.172) (0.650-1.123) (0.958-1.785)
0.833 0.260 0.091
RF- (94) 86 (45.7) 102 (54.3) 17 (18.1) 52 (55.3) 25 (26.6) 1.007 0.778 1.359
(0.740-1.371) (0.477-1.269) (0.777-2.376)
0.964 0.314 0.282
ACP (300) 281 (46.8) 319 (53.2) 62 (20.7) 157 (52.3) 81 (27.0) 1.052 0.794 1.152
(0.864-1.281) (0.584-1.080) (0.821-1.615)
0.612 0.142 0.413
ACPA - (113) 108 (47.8) 118 (52.2) 20 (17.7) 68 (60.2) 25 (22.1) 1.093 0.610 1.395
(0.822-1.453) (0.379-0.982) (0.830-2.345)
0.539 0.042* 0.209
Female control (465) 432 (46.5) 498 (53.5) 106 (22.8) 220 (47.3) 139 (29.9)
Female RA (482) 426 (44.2) 538 (55.8) 85 (17.6) 256 (53.1) 141 (29.3) 0.913 0.970 1.396
(0.762-1.094) (0.734-1.282) (1.015-1.920)
0.323 0.829 0.040
Female RF+ (333) 300 (45.0) 366 (55.0) 62 (18.6) 176 (52.9) 95 (28.5) 0.945 0.936 1.306
(0.774-1.154) (0.687-1.276) (0.920-1.855)
0.578 0.676 0.135
Female RF- (75) 64 (42.7) 86 (57.3) 12 (16.0) 40 (53.3) 23 (30.7) 0.858 1.037 1.569
(0.606-1.215) (0.611-1.761) (0.816-3.018)
0.388 0.892 0.177
Female ACPA+ (243) 225 (46.3) 261 (53.7) 50 (20.6) 125 (51.4) 68 (28.0) 0.994 0.911 1.154
(0.798-1.238) (0.647-1.285) (0.790-1.685)
0.956 0.596 0.459
Female ACPA- (84) 77 (45.8) 91 (54.2) 15 (17.9) 47 (56.0) 22 (26.2) 0.975 0.832 1.375
(0.701-1.356) (0.492-1.407) (0.756-2.502)
0.882 0.493 0.297
Male CON (105) 99 (47.1) 111 (52.9) 26 (24.8) 47 (44.8) 32 (30.5)
Male RA (121) 116 (47.9) 126 (52.1) 24 (19.8) 68 (56.2) 29 (24.0) 1.032 0.719 1.330
(0.713-1.495) (0.399-1.296) (0.709-2.496)
0.867 0.272 0.374
Male RF+ (84) 75 (44.6) 93 (55.4) 15 (17.9) 45 (53.6) 24 (28.6) 0.904 0.913 1.514
(0.602-1.359) (0.486-1.713) (0.742-3.088)
0.628 0.776 0.254
Male RF- (19) 22 (57.9) 16 (42.1) 5 (26.3) 12 (63.2) 2 (10.5) 1.542 0.268 0.922
(0.767-3.100) (0.059-1.231) (0.303-2.805)
0.222 0.090 0.886
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Table 2 Association analysis of rs7044343 with RA in the discovery population (Continued)
Male ACPA+ (57) 56 (49.1) 58 (50.9) 12 (21.1) 32 (56.1) 13 (22.8) 1.083 0.674 1.234
(0.686-1.709) (0.320-1.420) (0.568-2.681)
0.733 0.300 0.595
Male ACPA- (27) 29 (53.7) 25 (46.3) 5 (18.5) 19 (70.4) 3 (11.1) 1.301 0.285 1.448
(0.714-2.369) (0.080-1.016) (0.498-4.211)
0.390 0.053 0.497
*P < 0.05 versus controls; ACPAs, anti-citrullinated proteins antibodies; CI, confidence interval.
CON, healthy control; OR, odds ratio; RA, rheumatoid arthritis; RF, rheumatoid factor.
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Tag SNPs were selected according to the following prin-
ciples: (a) linkage disequilibrium (LD) between SNPs ac-
cording to Haploview (v. 4.2) based on HapMap CHB
data sets with the thresholds of r2 > 0.8 and D’ > 0.7 to
reduce the redundancy; (b) potential functional sites pre-
dicted by bioinformatics (Promoter and Genevar); and (c)
a minor allele frequency (MAF) threshold of >0.05. Data
were excluded if the allele call rate was <95%.
Genotyping of rs7044343 and 10975514 was performed
by using predesigned Taqman SNP Genotyping Assays
(C_31083545_10; Applied Biosystems, Foster City, CA,
USA). Allelic discrimination was performed in an ABI
7300 Real-Time PCR system (Applied Biosystems). The
successful genotyping rate was 99.0%.
The genotypes obtained were subsequently validated
and confirmed by sequencing the PCR products with an
ABI 3700 automated sequencer (Applied Biosystems). In
brief, 130 individuals of cases and controls were sequenced
for confirmation of the rs7044343 and rs10975514. The
results of DNA sequence analysis are shown in Additional
file 1: Figure S1. The confirmation rate was 100%.
Meta-analysis was performed by using Review Manager
5 software and carried out with the Mantel-Haenszel
method. A significant I2 statistic (I2 > 30%; P < 0.05) in-
dicated heterogeneity for OR across studies. The fixed-
effects model was applied in current meta-analyses.
Two genetic markers selected for the study, rs10975514
and rs7044343, were genotyped in the discovery popula-
tion. Then we further genotyped rs7044343 and 10975514
in the validation population and replication population.
Assay for serum levels of IL-33
Serum IL-33 was measured with enzyme-linked immuno-
sorbent assay (ELISA), according to the manufacturer’s in-
structions (R&D Systems, Minneapolis, MN, USA).
Statistical analyses
Allele frequencies were calculated and tested for agree-
ment with Hardy-Weinberg equilibrium (HWE) by using
a χ2 goodness-of-fit test. Differences in allele frequenciesand genotype distribution of the polymorphism between
RA cases and control subjects were compared by using a
2 × 2 contingency χ2 test with 1 degree of freedom, and
calculated odds ratios (ORs) with 95% confidence intervals
(CIs), adjusting for age and sex. Associations between gen-
etic variations and susceptibility or phenotype features of
RA were analyzed by using the Mann–Whitney U test. All
statistical analyses were conducted by using SPSS 16.0
(SPSS Inc., Chicago, IL, USA). A P value of <0.05 was con-
sidered statistically significant in the expression of IL-33.
Results
Population characteristics
The demographic distribution of the population under
study is shown in Table 1. The mean age in the case
group was 53.6 ± 13.3 years, and 81.3% were women.
The mean age at disease onset was 46.4 ± 15.6 years.
The positive rates of rheumatoid factor (RF) and ACPA
were 81.2% and 72.5%, respectively. The mean age of
healthy controls was 40.4 ± 10.3 years, and 80.6% were
women (Table 1).
Association analysis of rs7044343 with RA
In HapMap CHB (data resulted from sequencing of 42
individuals), the allele distributions for rs7044343 T and
C were 0.526 and 0.474 [11]. In our study, we found the
allele frequencies for rs7044343 T and C were 0.452 and
0.548 in the control subjects (n = 1,755). Based on the
assumption of a population prevalence of disease of
0.2%, α = 0.05, minor allele frequencies of 0.452, and
linkage disequilibrium of r2 = 0.8, the study had 99.7%
power to detect an additive association with an additive
OR of 1.26.
Allelic and genotype frequencies of rs7044343 SNP in
RA patients and controls are shown in Tables 2, 3, and
4. In the discovery population, the CC genotype of
rs7044343 was associated with (OR = 0.777; 95% CI,
0.611 to 0.988; P = 0.040) RA patients. When we divided
the RA patients into different subgroups by ACPA and
RF status, the results showed that the CC genotype of
rs7044343 was associated with RA patients without
Table 3 Association analysis of rs7044343 with RA in the validation population
Characteristic (n) Allele frequency (%) Genotype frequency (%) T vs. C CC vs. TT + TC CC + TC vs. TT
T C TT TC CC OR (95% CI) OR (95% CI) OR (95% CI)
P value P value P value
Control (456) 409 (44.8) 503 (55.2) 100 (21.9) 209 (45.8) 147 (32.2)
RA (586) 548 (46.8) 624 (53.2) 118 (20.1) 312 (53.2) 156 (26.6) 1.080 0.763 1.114
(0.908-1.285) (0.583-0.998) (0.825-1.504)
0.385 0.048* 0.480
RF + (354) 322 (45.5) 386 (54.5) 67 (18.9) 188 (53.1) 99 (28.0) 1.026 0.816 1.203
(0.842-1.250) (0.602-1.106) (0.851-1.701)
0.799 0.190 0.295
RF- (98) 100 (51.0) 96 (49.0) 25 (25.5) 50 (51.0) 23 (23.5) 1.281 0.645 0.820
(0.941-1.745) (0.388-1.070) (0.495-1.360)
0.116 0.089 0.442
ACPA + (281) 257 (45.7) 305 (54.3) 51 (18.1) 155 (55.2) 75 (26.7) 1.036 0.765 1.267
(0.839-1.280) (0.551-1.064) (0.870-1.845)
0.741 0.111 0.217
ACPA- (92) 94 (51.1) 90 (48.9) 21 (22.8) 52 (56.5) 19 (20.7) 1.284 0.547 0.950
(0.935-1.764) (0.318-0.940) (0.556-1.622)
0.121 0.029* 0.850
Female control (363) 319 (43.9) 407 (56.1) 75 (20.7) 169 (46.6) 119 (32.8)
Female RA (441) 413 (46.8) 469 (53.2) 87 (19.7) 239 (54.2) 115 (26.1) 1.124 0.723 1.060
(0.922-1.369) (0.533-0.982) (0.750-1.497)
0.247 0.038 0.743
Female RF+ (291) 264 (45.4) 318 (54.6) 53 (18.2) 158 (54.3) 80 (27.5) 1.059 0.777 1.169
(0.851-1.319) (0.554-1.090) (0.791-2.730)
0.607 0.144 0.433
Female RF- (75) 77 (51.3) 73 (48.7) 20 (26.7) 37 (49.3) 18 (24.0) 1.346 0.648 0.716
(0.946-1.914) (0.365-1.149) (0.404-1.268)
0.098 0.137 0.252
Female ACPA+ (234) 217 (46.4) 251 (53.6) 43 (18.4) 131 (56.0) 60 (25.6) 1.103 0.707 1.157
(0.873-1.393) (0.490-1.020) (0.762-1.755)
0.410 0.064 0.494
Female ACPA- (73) 74 (50.7) 72 (49.3) 18 (24.7) 38 (52.1) 17 (23.3) 1.311 0.622 0.796
(0.919-1.872) (0.347-1.118) (0.441-1.435)
0.135 0.112 0.448
Male CON (89) 86 (48.3) 92 (51.7) 24 (27.0) 38 (42.7) 27 (30.3)
Male RA (102) 98 (48.0) 106 (52.0) 23 (22.5) 52 (51.0) 27 (26.5) 0.956 0.827 1.268
(0.615-1.486) (0.440-1.553) (0.656-2. 452)
0.840 0.554 0.480
Male RF+ (63) 58 (46.0) 68 (54.0) 14 (22.2) 30 (47.6) 19 (30.2) 0.827 0.992 1.292
(0.527-1.299) (0.491-2.002) (0.607-2.753)
0.410 0.981 0.506
Male RF- (22) 23 (52.3) 21 (47.7) 5 (22.7) 13 (59.1) 4 (18.2) 1.172 0.510 1.255
(0.605-2.268) (0.158-1.651) (0.417-3.777)
0.638 0.261 0.686
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Table 3 Association analysis of rs7044343 with RA in the validation population (Continued)
Male ACPA+ (47) 40 (42.6) 54 (57.4) 8 (17.0) 24 (51.1) 15 (31.9) 0.792 1.076 1.800
(0.479-1.311) (0.502-2.306) (0.737-4.397)
0.365 0.850 0.197
Male ACPA- (18) 19 (52.8) 17 (47.2) 3 (16.7) 13 (72.2) 2 (11.1) 0.376 0.287 1.846
(0.207-0.686) (0.062-1.336) (0.491-6.946)
0.001 0.112 0.364
*P < 0.05 versus controls; ACPA anti-citrullinated proteins antibodies; CI confidence interval CON healthy controls; OR Odds ratio RA rheumatoid arthritis; RF
rheumatoid factor.
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No association was found between rs7044343 and RA
after gender stratification.
In the validation population and replication population,
the associations between rs7044343 and RA, especially
ACPA-negative RA, were still significant (OR = 0.763; 95%
CI, 0.583 to 0.998; P = 0.048; OR = 0.547, 95% CI 0.318-
0.940, P = 0.029; OR = 0.777, 95% CI 0.615 to 0.981,
P = 0.034; OR = 0.559, 95% CI, 0.337 to 0.927, P = 0.024).
A meta-analysis of discovery, validation, and replication
panels confirmed the association between CC genotype of
rs7044343 and RA (Pcombined = 0.0004; ORcombined = 0.77;
95% CI, 0.67 to -0.89). No evidence was noted for hetero-
geneity between the three sample sets (Phet = 0.99; I
2 = 0).
Similar results were also obtained in ACPA-negative RA
(Pcombined = 0.0002; ORcombined = 0.57; 95% CI, 0.43 to
0.77) (Figure 2). No association was detected between
rs10975514 polymorphism and RA susceptibility in the
discovery and validation population (see Additional file 2:
Table S1, Table S2, and Table S3).
No association was found between rs7044343 and
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), or 28-joint-count disease activity score (DAS28)
in RA (data not shown).
Patients with CC genotype of rs7044343 display lower
IL-33 serum levels
To evaluate whether IL33 polymorphism is associated
with dysregulation of IL-33 at the protein level, we con-
ducted ELISA assays of 141 sera of DMARDs-naïve RA
patients. The results showed that serum levels of IL-33
were significantly lower in RA patients with the rs7044343
CC genotype (n = 28) compared with the patients with
rs7044343 TT and TC genotypes (Figure 3b), indicating
that the CC genotype of rs7044343 downregulates IL-33
expression in RA. When we divided the patients into
ACPA-positive and -negative groups, the same result was
obtained in the ACPA-positive group (Figure 3c). In the
ACPA-negative group, patients with the CC genotype also
showed lower serum IL-33 level than did patients with TC
and TT genotypes (21.8 ± 40.5 versus 91.5 ± 209.5 versus125.1 ± 331.0 ng/ml); however, no statistical difference was
found. Moreover, IL-33 expression was significantly higher
in the dominant model (TT + TC) (P = 0.008; Figure 3d).Discussion
In the present study, we demonstrated that the CC
genotype of rs7044343 in IL33 is associated with RA pa-
tients, especially in the ACPA-negative subset. Results
also showed that the CC genotype of rs7044343 was as-
sociated with lower serum IL-33 levels. Genetic factors
contribute to the development of ACPA-negative RA as
much as ACPA-positive RA [12]. Only a few suscepti-
bility alleles of HLA and non-HLA genes have been as-
sociated with ACPA-negative RA [13]. From the present
data, gene polymorphism of IL33 is a new marker re-
lated to susceptibility to ACPA-negative RA.
The relation between the genotype of IL33 and the
production of autoantibodies is worth studying. Based
on the present study, the protective role provided by the
CC genotype of rs7044343 in RA patients may be due
to the impaired expression of IL-33 protein. The me-
chanisms by which IL-33 is associated with RA and its
specific antibodies production are still obscure. It was
deduced that IL-33 drove production of Th2-associated
cytokines, including IL-5 and IL-13, which could pro-
mote B-cell function, such as autoantibody production
[4]. IL-33 may also contribute to the antibody produc-
tion by inducing mast cell activation [6].
Genetic variants in IL33 were reported to be associated
with decreased risk of Alzheimer disease (AD) [14,15].
Chapuis et al. [14] showed that three intronic rs1157505,
rs11792633, and rs7044343 SNPs within IL33 decrease the
risk of AD. In this study, we found that a tag SNP-
rs7044343 in IL33 was also associated with RA. This indi-
cated that rs7044343 in IL33 decreased the risks of both
RA and AD. The inverse relation between AD and RA
was challenged. Simmons et al. [16] found that 17 alleles
associated with increased RA risk were not associated
with reduced AD risk, and three RA-associated SNPs
increased the risk of AD, indicating that RA genetics did
Table 4 Association analysis of rs7044343 with RA in the replication population
Characteristic (n) Allele frequency (%) Genotype frequency (%) T vs. C CC vs. TT + TC CC + TC vs. TT
T C TT TC CC OR (95% CI) OR (95% CI) OR (95% CI)
P-value P.-value P-value
Control (701) 631 (45.0) 771 (55.0) 154 (22.0) 323 (46.1) 224 (32.0)
RA (666) 632 (47.4) 700 (52.6) 144 (21.6) 344 (51.7) 178 (26.7) 1.103 0.777 1.021
(0.949-1.282) (0.615-0.981) (0.789-1.320)
0.201 0.034* 0.877
RF + (325) 300 (46.2) 350 (53.8) 73 (22.5) 154 (47.4) 98 (30.2) 1.047 0.919 0.972
(0.869-1.262) (0.691-1.223) (0.709-1.333)
0.627 0.563 0.860
RF-(62) 54 (43.5) 70 (56.5) 10 (16.1) 34 (54.8) 18 (29.0) 0.943 0.871 1.464
(0.651-1.365) (0.492-1.542) (0.727-2.948)
0.754 0.636 0.286
ACPA + (224) 192 (42.9) 256 (57.1) 39 (17.4) 114 (50.9) 71 (31.7) 0.916 0.988 1.335
(0.739-1.136) (0.715-1.365) (0.905-1.970)
0.425 0.943 0.2145
ACPA-(101) 103 (51.0) 99 (49.0) 23 (22.8) 57 (56.4) 21 (20.8) 1.271 0.559 0.955
(0.946-1.708) (0.337-0.927) (0.580-1.571)
0.111 0.024* 0.856
Female Control (519) 474 (45.7) 564 (54.3) 114 (22.0) 246 (47.4) 159 (30.6)
Female RA (458) 410 (44.8) 506 (55.2) 92 (20.1) 226 (49.3) 140 (30.6) 1.040 0.997 1.120
(0.869-1.246) (0.759-1.309) (0.822-1.525)
0.668 0.982 0.473
Female RF+ (256) 237 (46.3) 275 (53.7) 56 (21.9) 125 (48.8) 75 (29.3) 1.025 0.938 1.005
(0.829-1.268) (0.676-1.302) (0.700-1.444)
0.817 0.703 0.977
Female RF- (53) 46 (43.4) 60 (56.6) 8 (15.1) 30 (56.6) 15 (28.3) 0.912 0.894 1.583
(0.610-1.365) (0.478-1.672) (0.726-3.455)
0.655 0.725 0.248
Female ACPA+ (158) 133 (42.1) 183 (57.9) 27 (17.1) 79 (50.0) 52 (32.9) 0.865 1.111 1.366
(0.670-1.115) (0.759-1.625) (0.859-2.171)
0.263 0.589 0.187
Female ACPA- (76) 72 (47.4) 80 (52.6) 14 (18.4) 44 (57.9) 18 (23.7) 1.071 0.703 1.247
(0.761-1.506) (0.401-1.231) (0.673-2.308)
0.694 0.217 0.483
Male CON (130) 125 (48.1) 135 (51.9) 30 (23.1) 65 (50.0) 35 (26.9)
Male RA (95) 75 (39.5) 115 (60.5) 16 (16.8) 43 (45.3) 36 (37.9) 0.704 1.656 1.481
(0.482-1.029) (0.939-2.921) (0.754-2. 908)
0.070 0.081 0.254
Male RF+ (54) 42 (38.9) 66 (61.1) 10 (18.5) 22 (40.7) 22 (40.7) 0.687 1.866 1.320
(0.435-1.085) (0.958-3.636) (0.594-2.934)
0.107 0.067 0.496
Male RF- (9) 8 (44.4) 10 (55.6) 2 (22.2) 4 (44.4) 3 (33.3) 0.864 1.357 1.050
(0.330-2.259) (0.322-5.723) (0.207-5.325)
0.765 0.677 0.953
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Table 4 Association analysis of rs7044343 with RA in the replication population (Continued)
Male ACPA+ (44) 29 (33.0) 59 (67.0) 4 (9.1) 21 (47.7) 19 (43.2) 0.531 2.063 3.000
(0.320-0.881) (1.013-4.202) (0. 993–9.065)
0.014 0.046 0.052
Male ACPA- (11) 13 (59.1) 9 (40.9) 5 (45.5) 3 (27.3) 3 (27.3) 1.560 1.018 0.360
(0.644-3.776) (0.255-4.055) (0.103-1.263)
0.321 0.980 0.111
*P < 0.05 vs controls; RA rheumatoid arthritis; CON healthy controls; RF rheumatoid factor; ACPA anti-citrullinated proteins antibodies; OR Odds ratio; CI confidence
interval.
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rather may promote AD [17].
GWAS studies have shown that rs1342326 [16],
rs3939286 [18], and rs2381416 [19] SNPs within IL33
seem to be an asthma-susceptibility gene. IL33 encodes
a cytokine belonging to the IL1 superfamily, and is the
natural ligand for the IL1RL1 receptor [4], which has
been previously implicated in asthma, inflammation, and
a number of immune disorders [20].
The present study suggests a lack of association bet-
ween IL33 polymorphism and RA disease activity index
(including DAS 28 score, acute-phase reactant, and so
on), although the IL33 7044343 CC genotype was asso-
ciated with lower serum IL-33 levels. Whether the serum
levels of IL-33 were related to RA disease activity shows
conflicting evidence. Matsuyama et al. [21] reported that
serum IL-33 levels were significantly higher in RA pa-
tients and correlated with disease activity. However, wea       
b          
Figure 2 The allele model meta-analysis for rs7044343. A meta-analysis
between the CC genotype of rs7044343 and RA (Pcombined = 0.0004; ORcombine
between three sample sets (Phet = 0.99; I
2 = 0) (a). Similar results were also obt
0.43 to 0.77) (b).found that serum IL-33 levels were not correlated to
inflammation markers, such as ESR and CRP, but to
autoantibodies in RA patients, which was consistent
with the present finding.
Some limitations exist in our study. First, a larger sam-
ple size in different populations, especially in other ethnic
populations, is required to validate the results. Second,
although the results showed that the rs7044343 CC geno-
type of IL33 is associated with lower serum IL-33 levels,
more large-scale population study and functional experi-
ments are needed to elucidate the association. Third, the
rs7044343-polymorphism genotype distribution was not
in accordance with the HWE in RA patients and discovery
controls. Theoretically, cases do not need to be in HWE
[22]. Rs7044343 was not in HWE in discovery controls,
but was in HWE in validation and replication. This might
be due to the smaller sample size or to other uncertain
factors. We sequenced 130 cases and controls, and doubleof discovery, validation, and replication panels confirmed the association
d = 0.77; 95% CI, 0.67 to 0.89). No evidence was found for heterogeneity
































































































































Figure 3 Comparison of serum IL-33 levels among IL33 genotypes. The IL-33 levels were tested in 141 DMARDs-naïve RA patients and 115
healthy controls (HCs). Serum IL-33 concentrations were significantly higher in patients with RA than in healthy controls (P = 0.000 (a). Patients with
the CC genotype showed significantly lower serum IL-33 levels than did patients with TC and TT genotypes (b). When we divided the patients into
ACPA-positive and ACPA-negative groups, the same result was obtained in the ACPA-positive group (c). In the ACPA-negative group (n = 41), patients
with the CC genotype also showed lower serum IL-33 levels than did patients with TC and TT genotypes (21.8 ± 40.5 versus 91.5 ± 209.5 versus
125.1 ± 331.0 ng/ml); however, no statistical difference was found. IL-33 expression was significantly higher in the dominant model (TT + TC)
(P = 0.008 (d). TT, TC, and CC represent genotypes of IL33 rs7044343.
Li et al. Arthritis Research & Therapy 2014, 16:R105 Page 9 of 10
http://arthritis-research.com/content/16/2/R105checked the primer and probe sequences of SNPs and
genotype plots of TaqMan to confirm that no genotyping
bias existed.
Conclusion
To our knowledge, we first found that the rs7044343 in
IL33 is associated with RA patients, and the CC genotype
of rs7044343 is associated with lower serum IL-33 levels.
These findings, together with our previous studies, suggest
that IL-33, both in gene and in protein levels, plays an im-
portant role in the pathogenesis of RA.
Additional files
Additional file 1: Figure S1. DNA sequence analysis of the three
different genotypes of the rs7044343 and rs10975514. (a) The TT
genotype of rs7044343. (b) The CT genotype of rs7044343. (c) The CC
genotype of rs7044343. (d) The GG genotype of rs10975514. (e) The AG
genotype of rs10975514. (f) The AA genotype of rs10975514.
Additional file 2: Table S1. Association analysis of rs10975514 with RA
in the discovery population. Table S2. Association analysis of rs10975514
with RA in the validation population. Table S3. Association analysis of
rs10975514 with RA in the replication population.
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